Publication at Faculty of Medicine in Hradec Králové |
2019
Abstract
In the field of immunoallergology, monoclonal humanized antibodies are now used in the diagnosis of bronchial asthma, atopic eczema, chronic spontaneous urticaria and severe hyperplastic rhinosinusitis with nasal polyposis. Five molecules targeting the interleukin (IL) -5 pathway (mepolizumab, reslizumab, benralizumab) or the cytokine pathway IL-4 / IL-13 (dupilumab) or immunoglobulin E (omalizumab) are approved for the treatment of eosinophilic allergic and non-allergic asthma across the EU.